



InVivo Therapeutics Announces Closing of \$7.0 Million Public Offering

March 11, 2020

CAMBRIDGE, Mass.--([BUSINESS WIRE](#))--**InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV)** today announced the closing of its previously announced public offering of 2,545,455 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 2,545,455 shares of common stock at a combined effective price to the public of \$2.75 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering were approximately \$7.0 million, before deducting the placement agent fees and estimated offering expenses payable by InVivo Therapeutics.

H.C. Wainwright & Co. acted as exclusive placement agent for the offering.

A registration statement on Form S-1 (File No. 333-236572) relating to these securities has been filed with the Securities and Exchange Commission, or the SEC, and was declared effective by the SEC on March 6, 2020. The offering was made only by means of a prospectus, which is part of the effective registration statement. Electronic copies of the final prospectus may be obtained for free on the SEC's website located at <http://www.sec.gov> and may also be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, or by telephone at (646) 975-6996, or by email to placements@hcwco.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA.

Bret Shapiro, Managing Partner

CORE IR

Phone: (516) 222-2560

brets@coreir.com